Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Long-term tamoxifen citrate use and potential ocular toxicity.

Gorin MB, Day R, Costantino JP, Fisher B, Redmond CK, Wickerham L, Gomolin JE, Margolese RG, Mathen MK, Bowman DM, Kaufman DI, Dimitrov NV, Singerman LJ, Bornstein R, Wolmark N.

Am J Ophthalmol. 1998 Apr;125(4):493-501. Erratum in: Am J Ophthalmol 1998 Aug;126(2):338. Kaufmann D [corrected to Kaufman DI].

2.

Multifocal electroretinography, color discrimination and ocular toxicity in tamoxifen use.

Salomão SR, Watanabe SE, Berezovsky A, Motono M.

Curr Eye Res. 2007 Apr;32(4):345-52.

PMID:
17453956
3.

Ocular toxicity in low-dose tamoxifen: a prospective study.

Noureddin BN, Seoud M, Bashshur Z, Salem Z, Shamseddin A, Khalil A.

Eye (Lond). 1999 Dec;13 ( Pt 6):729-33.

PMID:
10707134
4.

Tamoxifen-associated eye disease. A review.

Nayfield SG, Gorin MB.

J Clin Oncol. 1996 Mar;14(3):1018-26. Review.

5.

Tamoxifen and ocular toxicity.

Ah-Song R, Sasco AJ.

Cancer Detect Prev. 1997;21(6):522-31. Review.

PMID:
9398992
6.

Retinal changes associated with tamoxifen treatment for breast cancer.

Tang R, Shields J, Schiffman J, Li H, Locher D, Hampton J, Prager T, Pardo G.

Eye (Lond). 1997;11 ( Pt 3):295-7. Review.

PMID:
9373465
7.

Eye problems in breast cancer patients treated with tamoxifen.

Paganini-Hill A, Clark LJ.

Breast Cancer Res Treat. 2000 Mar;60(2):167-72.

PMID:
10845279
8.

Crystalline maculopathy: a rare complication of tamoxifen therapy.

Srikantia N, Mukesh S, Krishnaswamy M.

J Cancer Res Ther. 2010 Jul-Sep;6(3):313-5. doi: 10.4103/0973-1482.73332.

9.

Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials.

Gianni L, Panzini I, Li S, Gelber RD, Collins J, Holmberg SB, Crivellari D, Castiglione-Gertsch M, Goldhirsch A, Coates AS, Ravaioli A; International Breast Cancer Study Group (IBCSG).

Cancer. 2006 Feb 1;106(3):505-13.

10.

Tamoxifen retinopathy: does it really exist?

Lazzaroni F, Scorolli L, Pizzoleo CF, Savini G, De Nigris A, Giosa F, Meduri RA.

Graefes Arch Clin Exp Ophthalmol. 1998 Sep;236(9):669-73.

PMID:
9782427
11.

Screening for ocular toxicity in asymptomatic patients treated with tamoxifen.

Heier JS, Dragoo RA, Enzenauer RW, Waterhouse WJ.

Am J Ophthalmol. 1994 Jun 15;117(6):772-5.

PMID:
7880223
12.

Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.

Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P, Stierer M, Holcombe C, Coleman RE, Jones L, Ellis I, Cuzick J; IBIS-II investigators.

Lancet. 2016 Feb 27;387(10021):866-73. doi: 10.1016/S0140-6736(15)01129-0. Epub 2015 Dec 11.

13.

Surveillance for uterine abnormalities in tamoxifen-treated breast carcinoma survivors: a community based study.

Althuis MD, Sexton M, Langenberg P, Bush TL, Tkaczuk K, Magaziner J, Khoo L.

Cancer. 2000 Aug 15;89(4):800-10.

PMID:
10951343
14.

Tamoxifen retinopathy in a male patient.

Yanyali AC, Freund KB, Sorenson JA, Slakter JS, Wheatley HM.

Am J Ophthalmol. 2001 Mar;131(3):386-7.

PMID:
11239879
15.

To stop or not? Tamoxifen therapy for secondary prevention of breast cancer in a patient with ocular toxicity.

Bommireddy T, Carrim ZI.

BMJ Case Rep. 2016 Jan 11;2016. pii: bcr2015213431. doi: 10.1136/bcr-2015-213431.

16.

Screening for tamoxifen ocular toxicity: a prospective study.

Therssen R, Jansen E, Leys A, Rutten J, Meyskens J.

Eur J Ophthalmol. 1995 Oct-Dec;5(4):230-4.

PMID:
8963159
17.

Retinal function in patients treated with tamoxifen.

Watanabe SE, Berezovsky A, Motono M, Sacai PY, Pereira JM, Sallum JM, Gebrim LH, Salomão SR.

Doc Ophthalmol. 2010 Apr;120(2):137-43. doi: 10.1007/s10633-009-9203-8.

PMID:
19911210
18.

The eyes have it! Tamoxifen maculopathy revisited: a case report.

Nair AG, Das D, Goyal A, Gandhi RA.

J Ocul Pharmacol Ther. 2012 Dec;28(6):640-2. doi: 10.1089/jop.2012.0050. Epub 2012 Jun 25.

PMID:
22731242
19.

Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.

Dominick S, Hickey M, Chin J, Su HI.

Cochrane Database Syst Rev. 2015 Dec 9;(12):CD007245. doi: 10.1002/14651858.CD007245.pub3. Review.

PMID:
26649916
20.

[Ocular toxicity caused by tamoxifen: case report].

Inada ET, Watanabe KP, Tanaka SG, Sakakisbara LA.

Arq Bras Oftalmol. 2005 Jul-Aug;68(4):554-6. Epub 2005 Nov 22. Portuguese.

Supplemental Content

Support Center